Brokerages Set Artivion, Inc. (NYSE:AORT) Target Price at $32.00

Shares of Artivion, Inc. (NYSE:AORT - Get Free Report) have earned a consensus rating of "Buy" from the seven research firms that are currently covering the company, MarketBeat reports. Six equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $32.00.

AORT has been the subject of several research reports. Canaccord Genuity Group initiated coverage on Artivion in a research note on Tuesday, June 17th. They set a "buy" rating and a $35.00 price target for the company. Citizens Jmp upgraded Artivion to a "strong-buy" rating in a report on Tuesday, May 6th. JMP Securities reiterated a "market outperform" rating and issued a $33.00 target price on shares of Artivion in a research note on Tuesday, May 6th. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $32.00 price objective on shares of Artivion in a research note on Tuesday, May 6th.

Artivion Stock Performance

Shares of AORT stock traded up $0.55 on Thursday, reaching $31.17. The stock had a trading volume of 543,052 shares, compared to its average volume of 340,675. The firm's 50-day moving average is $27.99 and its two-hundred day moving average is $27.53. Artivion has a 12 month low of $21.97 and a 12 month high of $32.33. The firm has a market capitalization of $1.33 billion, a price-to-earnings ratio of 122.48 and a beta of 1.62. The company has a quick ratio of 3.95, a current ratio of 5.53 and a debt-to-equity ratio of 1.08.

Artivion (NYSE:AORT - Get Free Report) last announced its quarterly earnings results on Monday, May 5th. The company reported $0.06 EPS for the quarter, missing analysts' consensus estimates of $0.12 by ($0.06). Artivion had a negative net margin of 5.49% and a positive return on equity of 3.63%. The firm had revenue of $98.98 million during the quarter, compared to the consensus estimate of $94.81 million. On average, research analysts expect that Artivion will post 0.37 EPS for the current fiscal year.

Insider Buying and Selling

In related news, SVP Jean F. Holloway sold 8,748 shares of the business's stock in a transaction dated Tuesday, May 27th. The shares were sold at an average price of $29.00, for a total transaction of $253,692.00. Following the completion of the sale, the senior vice president now owns 178,510 shares of the company's stock, valued at $5,176,790. This represents a 4.67% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Marshall S. Stanton sold 26,132 shares of the business's stock in a transaction that occurred on Friday, June 13th. The stock was sold at an average price of $28.44, for a total value of $743,194.08. Following the transaction, the senior vice president now owns 79,200 shares of the company's stock, valued at approximately $2,252,448. This represents a 24.81% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 72,954 shares of company stock worth $2,108,525. Corporate insiders own 7.60% of the company's stock.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in AORT. Franklin Resources Inc. raised its holdings in shares of Artivion by 2.8% in the fourth quarter. Franklin Resources Inc. now owns 21,707 shares of the company's stock valued at $621,000 after buying an additional 600 shares during the last quarter. Illinois Municipal Retirement Fund lifted its holdings in shares of Artivion by 3.1% in the first quarter. Illinois Municipal Retirement Fund now owns 20,519 shares of the company's stock valued at $504,000 after purchasing an additional 611 shares in the last quarter. MCF Advisors LLC grew its position in Artivion by 109.3% in the first quarter. MCF Advisors LLC now owns 1,176 shares of the company's stock valued at $29,000 after purchasing an additional 614 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Artivion by 3.3% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,559 shares of the company's stock valued at $645,000 after buying an additional 727 shares during the last quarter. Finally, Smartleaf Asset Management LLC increased its position in Artivion by 236.7% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,118 shares of the company's stock worth $32,000 after buying an additional 786 shares during the last quarter. Institutional investors and hedge funds own 86.37% of the company's stock.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.